Intranasal microemulsion based brain delivery system of rivastigmine: formulation and ex-vivo characterization
- At: PSWC, Melbourne (Australia) (2014)
- Type: Poster
- By: SHAH BRIJESH, Maheshkumar (B.V. Patel Pharmaceutical Education & Research Development (PERD) Centre, Pharmaceutical Technology, Ahmedabad, India)
- Co-author(s): Misra, Manju (National Institute of Pharmaceutical Education and Research, Ahmedabad, India)
Padh, Harish (Sardar Patel University, Anand, India)
Alzheimer's disease is a progressive neurodegenerative disorder leading to irreversible loss of neurons, cognition and formation of abnormal protein aggregates. Rivastigmine, a reversible cholinesterase inhibitor used for the treatment of Alzheimer's disease, undergoes extensive first-pass metabolism, thus limiting its absolute bioavailability to.. The access to the whole abstract and the presentation file is available to FIP members and to congress participants of that specific congress.